Next Day Disclosure Return
Filed with HKEX · Stock code 9926 · · 6 pages · English
Earlier from Akeso
- Completion of placing of new shares under general mandate
- Placing of new shares under general mandate
- Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2026
- 2026 Interim report
- Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
Later from Akeso
- Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab
- VOLUNTARY ANNOUNCEMENT - HARMONI-GI1 RESULTS PUBLISHED AT 2026 ESMO mOS 14.9m vs 12.1m, HR 0.75 (P=0.0031) FOR IVONESCIMAB PLUS CHEMO VS DURVALUMAB PLUS CHEMO IN 1L ADVANCED BTC
Follow Akeso into a list and get an email when it puts out news.
Follow Akeso